Form 4: Neogenomics Director Lynn A. Tetrault Reports Stock Option and Restricted Stock Unit Acquisition
SEC Form 4 Filing
Director Lynn A. Tetrault reports acquisition of stock options and restricted stock units in Neogenomics Inc.
Summary
- On June 4, 2024, Lynn A. Tetrault, a director of Neogenomics Inc., filed a Form 4 with the SEC.
- The report details the acquisition of stock options and restricted stock units.
- Tetrault acquired 8,672 stock options with an exercise price of $13.71, exercisable from June 1, 2025, and expiring on June 1, 2034.
- Additionally, Tetrault acquired 12,254 restricted stock units, vesting from June 1, 2025.
- The filing also shows Tetrault directly owns 50,062 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options and restricted stock units by a director suggests confidence, but it's a routine transaction.
Positives
- The acquisition of stock options and restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but the acquisition of stock options and restricted stock units suggests a belief in the company's future growth.
Industry Context
This filing is a routine disclosure related to insider transactions and provides insight into management's compensation structure and ownership stake in Neogenomics.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, reflecting insider confidence.
Key Dates
| Date | Description |
|---|---|
| 06/06/2020 | Date of stock option grant with exercise price $22.52, expiring 06/06/2026 |
| 05/28/2021 | Date of stock option grant with exercise price $28.54, expiring 05/28/2027 |
| 06/02/2022 | Date of stock option grant with exercise price $40.9, expiring 06/02/2028 |
| 10/11/2022 | Date of stock option grant with exercise price $41.76, expiring 10/11/2028 |
| 06/10/2023 | Date of stock option grant with exercise price $8.1, expiring 06/10/2029 |
| 08/10/2024 | Date of stock option grant with exercise price $14.82, expiring 08/10/2033 and Restricted Stock Unit grant |
| 06/01/2024 | Date of transaction for stock option and restricted stock unit acquisition |
| 06/01/2025 | Date stock options and restricted stock units become exercisable/vest |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.